| Authors: |
Alsina M; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida., Shah N; Division of Hematology and Oncology, University of California, San Francisco, California., Jagannath S; Department of Hematology and Medical Oncology, Tisch Cancer Institute, Mount Sinai Medical Center, New York, New York., Kaufman JL; Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia., Siegel D; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey., Munshi NC; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Rosenblatt J; Beth Israel Deaconess Medical Center, Boston, Massachusetts., Lin Y; Mayo Clinic , Rochester, Minnesota., Jakubowiak AJ; University of Chicago , Chicago, Illinois., Derman BA; University of Chicago , Chicago, Illinois., Li A; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Mao P; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Fincker M; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Yeri A; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Martin N; Bristol Myers Squibb , Princeton, New Jersey., Campbell TB; Bristol Myers Squibb , Princeton, New Jersey., Finney O; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Truppel-Hartmann A; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Petrocca F; 2seventy bio., a Bristol Myers Squibb Company, Princeton, New Jersey., Berdeja JG; Sarah Cannon Research Institute and Tennessee Oncology, Nashville, Tennessee., Raje N; Massachusetts General Hospital Cancer Center, Boston, Massachusetts. |
